Comparative Pharmacology
Head-to-head clinical analysis: NOVAMINE 11 4 versus NOVAMINE 8 5.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NOVAMINE 11 4 versus NOVAMINE 8 5.
NOVAMINE 11.4% vs NOVAMINE 8.5%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amino acid solution providing essential and non-essential amino acids for protein synthesis and nitrogen balance in parenteral nutrition.
Novamine 8.5% is a crystalline amino acid solution that provides essential and non-essential amino acids for protein synthesis and nitrogen balance in patients who cannot obtain adequate nutrition enterally.
Intravenous infusion: initial dose 1.5 mL/kg/day (0.17 g amino acids/kg/day) increased by 0.5 mL/kg/day to 2.0-3.0 mL/kg/day (0.23-0.34 g amino acids/kg/day) maximum 3.5 mL/kg/day (0.4 g amino acids/kg/day). Infusion rate not to exceed 0.1 mL/kg/hour in neonates and 0.2 mL/kg/hour in older patients.
500 mL to 2000 mL intravenously per 24 hours, typically infused at a rate of 20 to 40 mL/hour; adjust based on metabolic and clinical response.
None Documented
None Documented
Variable, dependent on amino acid profile; net protein synthesis occurs over 4-6 hours post-infusion; no classical terminal half-life; clinical steady state achieved within 24-48 hours of continuous infusion.
Variable; amino acids have short t1/2 of minutes to hours. Clinical context: continuous infusion maintains steady state; elimination depends on metabolic demand and organ function.
Amino acids are metabolized via transamination and deamination; nitrogen is excreted renally as urea (75-90%), with minimal biliary/fecal elimination (<5%).
Renal: >95% as amino acids and metabolites. Biliary/fecal: <5%.
Category C
Category C
Parenteral Nutrition
Parenteral Nutrition